Association between TCF7L2 genotype and glycemic control in diabetic patients treated with gliclazide

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Javorský, Martin ^a   Babjaková, Eva ^a   Klimčáková, Lucia ^b   Schroner, Zbynek ^a   Židzik, Jozef ^b   Štolfová, Mária ^a   Šalagovič, Ján ^b   Tkáč, Ivan ^a  

^a L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

^b P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA DERIVATIVE; TRANSCRIPTION FACTOR 7 LIKE 2;

ADD ON THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC MODEL; GENOTYPE; GLYCEMIC CONTROL; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; TCF7L2 GENE;

EID: 84874894776     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/374858     Document Type: Article

References (23)

1. Gribble F. M., Reimann F., Sulphonylurea action revisited: the post-cloning era. Diabetologia 2003 46 7 875 891 2-s2.0-0042071600 10.1007/s00125-003-1143-3 (Pubitemid 36961311)
2. Shyng S. L., Nichols C. G., Octameric stoichiometry of the KATP channel complex. Journal of General Physiology 1997 110 6 655 664 2-s2.0-0030609143 10.1085/jgp.110.6.655 (Pubitemid 27524606)
3. Florez J. C., Burtt N., De Bakker P. I. W., Almgren P., Tuomi T., Holmkvist J., Gaudet D., Hudson T. J., Schaffner S. F., Daly M. J., Hirschhorn J. N., Groop L., Altshuler D., Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 2004 53 5 1360 1368 2-s2.0-2342561802 10.2337/diabetes.53.5.1360 (Pubitemid 38569024)
4. Lang V., Fatehi M., Light P. E., Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A. Pharmacogenetics and Genomics 2012 22 3 206 214 10.1097/FPC.0b013e32835001e7
5. Feng Y., Mao G., Ren X., Xing H., Tang G., Li Q., Li X., Sun L., Yang J., Ma W., Wang X., Xu X., Ser 1369Ala variant in sulfonylurea receptor gene ABCC8 Is associated with antidiabetic efficacy of gliclazide in Chinese Type 2 diabetic patients. Diabetes Care 2008 31 10 1939 1944 2-s2.0-56149106823 10.2337/dc07-2248
6. Javorsky M., Klimcakova L., Schroner Z., KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. European Journal of Internal Medicine 2012 23 3 245 249 10.1016/j.ejim.2011.10.018
7. Grant S. F. A., Thorleifsson G., Reynisdottir I., Benediktsson R., Manolescu A., Sainz J., Helgason A., Stefansson H., Emilsson V., Helgadottir A., Styrkarsdottir U., Magnusson K. P., Walters G. B., Palsdottir E., Jonsdottir T., Gudmundsdottir T., Gylfason A., Saemundsdottir J., Wilensky R. L., Reilly M. P., Rader D. J., Bagger Y., Christiansen C., Gudnason V., Sigurdsson G., Thorsteinsdottir U., Gulcher J. R., Kong A., Stefansson K., Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nature Genetics 2006 38 3 320 323 2-s2.0-32544451924 10.1038/ng1732
8. Tong Y., Lin Y., Zhang Y., Yang J., Zhang Y., Liu H., Zhang B., Association between TCF7L2 gene polymorphisms and susceptibility to Type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Medical Genetics 2009 10, article 15 2-s2.0-61849101938 10.1186/1471-2350-10-15
9. Florez J. C., Jablonski K. A., Bayley N., Pollin T. I., De Bakker P. I. W., Shuldiner A. R., Knowler W. C., Nathan D. M., Altshuler D., TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. The New England Journal of Medicine 2006 355 3 241 250 2-s2.0-33746075560 10.1056/NEJMoa062418 (Pubitemid 44079339)
10. Saxena R., Gianniny L., Burtt N. P., Lyssenko V., Giuducci C., Sjögren M., Florez J. C., Almgren P., Isomaa B., Orho-Melander M., Lindblad U., Daly M. J., Tuomi T., Hirschhorn J. N., Ardlie K. G., Groop L. C., Altshuler D., Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006 55 10 2890 2895 2-s2.0-33750892139 10.2337/db06-0381 (Pubitemid 44923692)
11. Pearson E. R., Donnelly L. A., Kimber C., Whitley A., Doney A. S. F., McCarthy M. I., Hattersley A. T., Morris A. D., Palmer C. N. A., Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007 56 8 2178 2182 2-s2.0-34547585382 10.2337/db07-0440 (Pubitemid 47195841)
12. Schroner Z., Javorsky M., Tkacova R., Klimcakova L., Dobrikova M., Habalova V., Kozarova M., Zidzik J., Rudikova M., Tkac I., Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2011 13 1 89 91 2-s2.0-78649693563 10.1111/j.1463-1326.2010.01324.x
13. Holstein A., Hahnl M., Körner A., Stumvoll M., Kovacs P., TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Medical Genetics 2011 24 12 30
14. Seino S., Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea. Diabetologia 2012 55 8 2096 2108 10.1007/s00125-012-2562-9
15. Winkler M., Stephan D., Bieger S., Kühner P., Wolff F., Quast U., Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands. Journal of Pharmacology and Experimental Therapeutics 2007 322 2 701 708 2-s2.0-34547116194 10.1124/jpet.107.123224 (Pubitemid 47105784)
16. American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 2006 29 Supplement 1 S43 S48
17. Liu Z., Habener J. F., Glucagon-like peptide-1 activation of TCF7L2 -dependent Wnt signaling enhances pancreatic beta cell proliferation. Journal of Biological Chemistry 2008 283 13 8723 8735 2-s2.0-43749120731 10.1074/jbc.M706105200
18. Preitner F., Ibberson M., Franklin I., Binnert C., Pende M., Gjinovci A., Hansotia T., Drucker D. J., Wollheim C., Burcelin R., Thorens B., Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. Journal of Clinical Investigation 2004 113 4 635 645 2-s2.0-11144357764 10.1172/JCI200420518 (Pubitemid 38542513)
19. Shibasaki T., Takahashi H., Miki T., Sunaga Y., Matsumura K., Yamanaka M., Zhang C., Tamamoto A., Satoh T., Miyazaki J. I., Seino S., Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proceedings of the National Academy of Sciences of the United States of America 2007 104 49 19333 19338 2-s2.0-37649002935 10.1073/pnas.0707054104
20. Zhang C. L., Katoh M., Shibasaki T., Minami K., Sunaga Y., Takahashi H., Yokoi N., Iwasaki M., Miki T., Seino S., The cAMP sensor epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 2009 325 5940 607 610 2-s2.0-68149136367 10.1126/science.1172256
21. Villareal D. T., Robertson H., Bell G. I., Patterson B. W., Tran H., Wice B., Polonsky K. S., TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010 59 2 479 485 2-s2.0-77449099615 10.2337/db09-1169
22. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C. E., Pan C., Poulter N., Rodgers A., Williams B., Bompoint S., De Galan B. E., Joshi R., Travert F., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine 2008 358 24 2560 2572 2-s2.0-45149133036 10.1056/NEJMoa0802987 (Pubitemid 351831357)
23. Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., Novials A., Rottiers R., Rutten G. E. H. M., Shaw K. M., Guide study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. European Journal of Clinical Investigation 2004 34 8 535 542 2-s2.0-4344693381 10.1111/j.1365-2362.2004.01381.x (Pubitemid 39120222)